Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis.

IF 1.5 Q3 CRITICAL CARE MEDICINE

Indian Journal of Critical Care Medicine Pub Date : 2024-10-01 Epub Date: 2024-09-30 DOI:10.5005/jp-journals-10071-24805

Indranil Ghosh, Sukhwinder Sangha, Gaurav Pandey, Atul Srivastava

{"title":"Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis.","authors":"Indranil Ghosh, Sukhwinder Sangha, Gaurav Pandey, Atul Srivastava","doi":"10.5005/jp-journals-10071-24805","DOIUrl":null,"url":null,"abstract":"Objectives: To study the efficacy of polymyxin B hemoperfusion in addition to standard care for sepsis treatment.Materials and methods: Fifty sepsis patients (mean age 54.26 ± 14.64 years; 68% males) were randomized to either the case group (n = 25; receiving Polymyxin B hemoperfusion in addition to standard ICU care) or the control group (n = 25; receiving standard ICU care only). The patients were followed up at frequent intervals of 6, 12, 24, 48, and 72 hours. A last follow-up on day 7 was done. The duration of the ICU stay and survival until day 7 were recorded. Changes in clinical and biochemical parameters were also noted and compared.Results: Mean sequential organ failure assessment (SOFA) scores at admission were 3.44 ± 1.00 and 2.80 ± 0.82, respectively, in cases and controls. Cases as compared to controls showed faster, and sustainable improvement. No significant difference between the two groups was seen for mortality at day 7.Conclusion: Polymyxin B hemoperfusion tends to show a faster recovery and a non-significant trend towards reduced mortality in ICU-admitted sepsis patients.How to cite this article: Ghosh I, Sangha S, Pandey G, Srivastava A. Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis. Indian J Crit Care Med 2024;28(10):930-934.","PeriodicalId":47664,"journal":{"name":"Indian Journal of Critical Care Medicine","volume":"28 10","pages":"930-934"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471987/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10071-24805","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To study the efficacy of polymyxin B hemoperfusion in addition to standard care for sepsis treatment.

Materials and methods: Fifty sepsis patients (mean age 54.26 ± 14.64 years; 68% males) were randomized to either the case group (n = 25; receiving Polymyxin B hemoperfusion in addition to standard ICU care) or the control group (n = 25; receiving standard ICU care only). The patients were followed up at frequent intervals of 6, 12, 24, 48, and 72 hours. A last follow-up on day 7 was done. The duration of the ICU stay and survival until day 7 were recorded. Changes in clinical and biochemical parameters were also noted and compared.

Results: Mean sequential organ failure assessment (SOFA) scores at admission were 3.44 ± 1.00 and 2.80 ± 0.82, respectively, in cases and controls. Cases as compared to controls showed faster, and sustainable improvement. No significant difference between the two groups was seen for mortality at day 7.

Conclusion: Polymyxin B hemoperfusion tends to show a faster recovery and a non-significant trend towards reduced mortality in ICU-admitted sepsis patients.

How to cite this article: Ghosh I, Sangha S, Pandey G, Srivastava A. Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis. Indian J Crit Care Med 2024;28(10):930-934.

查看原文本刊更多论文

多粘菌素 B 血液灌流治疗败血症的疗效。

目的：研究多粘菌素 B 血液灌流治疗败血症的疗效：研究多粘菌素B血液灌流在脓毒症治疗标准护理之外的疗效：将 50 名脓毒症患者（平均年龄为 54.26 ± 14.64 岁；68% 为男性）随机分为病例组（n = 25；在接受标准重症监护室护理的同时接受多粘菌素 B 血液灌流）或对照组（n = 25；仅接受标准重症监护室护理）。每隔 6、12、24、48 和 72 小时对患者进行一次随访。最后一次随访在第 7 天进行。记录了重症监护室的住院时间和第 7 天前的存活率。同时还记录并比较了临床和生化指标的变化：结果：病例和对照组入院时的器官功能衰竭顺序评估（SOFA）平均得分分别为 3.44 ± 1.00 和 2.80 ± 0.82。与对照组相比，病例的病情改善更快、更持久。两组患者在第 7 天的死亡率无明显差异：结论：多粘菌素 B 血液灌流可使重症监护室收治的脓毒症患者更快康复，并有降低死亡率的非显著趋势：Ghosh I, Sangha S, Pandey G, Srivastava A. 多粘菌素B血液灌流治疗败血症的疗效。Indian J Crit Care Med 2024;28(10):930-934.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Journal of Critical Care Medicine CRITICAL CARE MEDICINE-

CiteScore

3.50

自引率

10.00%

发文量

299

期刊介绍： Indian Journal of Critical Care Medicine (ISSN 0972-5229) is specialty periodical published under the auspices of Indian Society of Critical Care Medicine. Journal encourages research, education and dissemination of knowledge in the fields of critical and emergency medicine.